Furthermore, affibody molecules, ADAPTs, and DARPins have been used successfully to target HER2-positive tumors in breast cancer patients for radionuclide molecular imaging of HER2 status in Phase I clinical trials [10,11,12]. This evidence concerns the gene ERBB2 and breast carcinoma.